WILL HE BE WEARING CHILDREN'S CLOTHES WHEN HE'S A GROWN-UP?

Somatonorm® (somatrem) is successfully changing the outlook for this child and thousands like him suffering from short stature caused by growth hormone deficiency (GHD).

With early diagnosis and treatment, GHD children can achieve a normal adult height.

For the past two decades, KabiVitrum has pioneered growth hormone research.

The introduction of Somatonorm ensures that, for the first time, sufficient growth hormone is available to treat all GHD children.

Prescribing Information

Presentation A vial of sterile lyophilised powder of somatrem corresponding to 4IU of human somatotropin (also containing aminoacetic acid and sodium phosphate as stabilisers) and supplied with a 2ml ampoule of water for injections for use in the reconstitution of the injection.

Uses The treatment of short stature caused by decreased or absent secretion of pituitary growth hormone. The diagnosis should be verified by appropriate investigations of pituitary function by a specialist medical practitioner.

Dosage and Administration Route of administration: By intramuscular injection. Recommended dosage: The dosage should be calculated according to the patient's body weight. Generally a dose of 0.5 IU/kg body weight per week is recommended. This weekly dose should be divided into 2 or 3 intramuscular injections.

Contra-indications, warnings, etc. Only patients with unfused epiphyses should be treated. Diabetes mellitus. Precautions: Patients treated with Somatonorm should be regularly assessed by a specialist in child growth. Side-effects: Clinical experience with Somatonorm is limited and recipients may develop antibody to growth hormone and E. coli protein. However, as with pituitary derived hormone, only in very rare instances has growth retardation occurred. No other adverse reactions have been noted.

Package Quantities Combined package containing one vial of somatrem 4 IU and one ampoule of 2ml water for injections.

Price NHS Price £28.

Further Information Somatrem is the British Approved Name for methionyl human somatotropin.

Product Licence Number 0022/0060.

KabiVitrum Limited, KabiVitrum House, Riverside Way, Uxbridge, Middx UB8 2YF.

Product Authorisation Number 187/28/1.

Eire KabiVitrum, Cahill May Roberts Ltd, P.O. Box 1090, Chapelizod, Dublin 20.

GROWTH SERVICE
KABIVITRUM

HE WANTS TO GROW. KabiVitrum CAN HELP HIM.

KV628 11/86



Insulin with a future

In 1922, Lilly led the world in insulin technology when their co-operation with Banting and Best resulted in the first large scale production of insulin.

Lilly is still the world's largest manufacturer of insulin.

Lilly was the first to manufacture insulin by genetic engineering – technology which assures future supplies of insulin.

Humulin
Human Insulin (prb)

The first genetically engineered human insulin

Monatsschrift Kinderheilkunde

Organ der Deutschen Gesellschaft für Kinderheilkunde

135. Band
Heft 6
Juni 1987

Springer-Verlag
Berlin Heidelberg New York London
Paris Tokyo

	Thema des Monats	**This Month's Topic**	
	Kinder- und jugendpsychiatrische Probleme: Teilleistungsschwächen Legasthenie	Psychiatric Problems in Children and Juveniles: Specific Developmental Disorders Dyslexia	289
H. Remschmidt	Was sind Teilleistungsschwächen?	What is a Specific Developmental Disorder?	290
G. Niebergall	Diagnostische Aspekte der Legasthenie	Diagnostic Aspects of Dyslexia (Legasthenie)	297
A. Warnke	Behandlung der Legasthenie im Kindesalter	Treatment of Dyslexia in Children	302
	Pädiatrie aktuell	**Trends in Paediatrics**	308
	Was hat das Kind?	**What's Wrong with the Child?**	
	Trainingsprogramm für die Weiterbildung zum Kinderarzt	**Program for Continuing Education of Paediatricians**	309
	Aus Klinik und Forschung Originalien	**Clinics and Research Originals**	
St. König, D. Scheffner, I. Rauterberg-Ruland, W. Kochen, W. J. Hofmann, E. Wokittel, U. Schick	Tödliches Leberversagen bei einem altersgemäß entwickelten fünf Jahre alten Jungen unter VPA-Monotherapie	Fatal Hepatotoxicity in a Normally Developed Five Year Old Boy on Valproate Monotherapy	310
M. Kersting, T. Wember, T. Goddemeier, H. Koester, J. Wennemann, G. Schöch	Stillstudien 1981 – 1983 bei 1500 Müttern in Dortmund und Haltern. III. Stillraten und Stilldauer im 1. Lebenshalbjahr	Studies on Breast-Feeding 1981 – 1983 with 1500 Mothers in Dortmund and Haltern. III. Breast-Feeding Rates and Duration in the First 6 Months	314
J. M. Nußbaum, K. G. Diller, B. Reitter	Progressive Muskeldystrophie Duchenne: Praxis der Diagnosefindung	How to Diagnose Duchenne's Muscular Dystrophy	320
D. Körholz, R. Urbanek, W. Nürnberger, A. Jobke, U. Göbel, V. Wahn	Bildung spezifischer IgG-Antikörper unter 1-Asparaginasebehandlung. Verteilung der IgG-Subklassen	Development of Specific IgG-Antibodies During 1-Asparaginase Treatment. Distribution of IgG-Subclasses	325
M. Gahr, B. Allgeier, Ch. P. Speer	Das Hyper-IgE-Syndrom	Hyper-IgE-Syndrome	329
	Der interessante Fall	**Interesting Cases**	
E. Mühler, U. Gurr, H. Hörnchen	Zweizeitige intracerebrale Blutung bei neonataler Alloimmunthrombozytopenie	Intrauterine and Perinatal Intracranial Haemorrhage in Neonatal Alloimmune Thrombocytopenia	336
K. Pistor, K. Heemann, H. Olbing	Asymptomatische Hypokaliämie und Hypomagnesiämie mit renalem Kationenverlust (Gitelman-Syndrom)	Asymptomatic Renal Wasting of Potassium and Magnesium – Gitelman-Syndrome	340
	Wußten Sie schon?	**Do You Know?**	
	Aus der Praxis – für die Praxis	*Practical Tips for Practitioners*	
H. Moll	Infektiöse Hepatitis	Infectious Hepatitis	343
	Auflösung und Kommentar des Trainingsprogramms für die Weiterbildung zum Kinderarzt	Solution and Commentary in the Program for Continuing Education of Paediatricians	313
	Briefe an die Redaktion – Diskussion	**Letters to the Editor**	
Th. Paul, E. Trowitzsch, M. Barthels, H. C. Kallfelz	Antwort auf die Bemerkungen von W. Burmeister zur Arbeit „Kavernöses Hämangiom und Verbrauchskoagulopathie (Kasabach-Merritt-Syndrom) bei einem Neugeborenen mit einem großen Ventrikelseptumdefekt" Monatsschr Kinderheilkd 135:173	Remarks on the Comment by W. Burmeister on „Cavernous Hemangioma and Consumption Coagulopathy (Kasabach-Merritt-Syndrome) in a Newborn with a Large Ventricular Septal Defect" Monatsschr Kinderheilkd 135:173	343
W. Burmeister	Zur Arbeit „Besonderheiten der Arzneimitteltherapie im Kindesalter" von D. Reinhardt und D. Kusenbach Monatsschr Kinderheilkd 134:772 – 778	Comment on „Special Features of Drug Therapy in Children" by D. Reinhardt and G. Kusenbach Monatsschr Kinderheilkd 134:772 – 778	344
D. Reinhardt	Antwort auf vorstehende Bemerkungen von W. Burmeister	Remarks of the Comment by W. Burmeister	344
	Laudationes	**Laudationes**	
D. Reinhardt	Prof. Dr. Gustav-Adolf von Harnack 70 Jahre	Prof. Dr. Gustav-Adolf von Harnack 70 Years	345
	Aus Gesellschaften und Berufsverband	**Society and Professional Organisations**	346
	Neue Bücher	**New Books**	347
	Tagesgeschichte, Personalia	**News of the Day, Personal News**	347
	Tagungskalender	**Forthcoming Meetings**	347
	Für die Dokumentation	**Documentation**	A 38

Indexed in Current Contents

Monatsschr Kinderheilkd (1987) 135, 6

Annual subscription: DM 288,- plus postage

Simonsen & Weel care... about Neonates.







Monitoring for Neonates
The introduction of the Neopack range of Neonatal monitors, each based on the unique Neoscope, now means that all known neonatal monitoring applications can be catered for. From the simple Diascope 1, through to the most sophisticated combinations of monitors from our extensive range of Simonsen & Weel monitors help to care for neonates.

Pulse Oximetry for Neonates
With the purpose built neonatal sensor the Criticare is ideal for the continuous monitoring of oxygen saturation in the newborn. This simple to use reliable monitor, gives a clear digital display of the $\%0_2$ Saturation and pulse rate, all in a compact, portable and mains/battery operated unit.

Incubators for Neonates
A safe, stable controlled environment is needed for the premature infant. The Ameda range of incubators offers a wide choice, with the Amelette and Amecare. For those occasions when a closed incubator is not required the Ametherm represents a real alternative.

Simonsen & Weel Ltd,
Ruxley Corner, Sidcup, Kent DA14 5BL.
Tel: 01-309 0433. Telex: 896328.

S&W

Epilim®
Sodium Valproate

In a wide range of epilepsies

Presentation 1. Epilim 200 Enteric Coated. A lilac-coloured, enteric coated tablet containing 200mg Sodium Valproate B.P. 2. Epilim 500 Enteric Coated. A lilac-coloured, enteric coated tablet containing 500mg Sodium Valproate B.P. 3. Epilim 100mg crushable tablets. A white, scored tablet containing 100mg Sodium Valproate B.P. 4. Epilim Syrup. A red, cherry-flavoured syrup containing 200mg Sodium Valproate B.P. per 5ml. 5. Epilim Liquid. A red, cherry-flavoured, sugar-free liquid containing 200mg Sodium Valproate B.P. per 5ml. **Indications** In the treatment of generalised, partial or other epilepsies. In women of child-bearing age Epilim should be used only in severe cases or in those resistant to other treatment. **Dosage and Administration** To be taken with or after food. Epilim may be given twice daily. Enteric coated tablets should be swallowed whole. **Monotherapy** *Adults:* Start at 600mg daily increasing by 200mg at 3 day intervals until control is achieved. (Maximum dose 2,500mg per day.) *Children over 20kg:* Initially 400mg/day with spaced increases until control is achieved. (Usually within the range 20-30mg/kg body weight per day.) *Children under 20kg:* 20mg/kg of body weight per day: in severe cases may be increased up to 40mg/kg/day. Increases above this only if plasma valproic acid levels, clinical chemistry and haematological parameters can be monitored. **Combined Therapy** It may be necessary to raise the dose when used with anticonvulsants which induce liver enzyme activity. Dosage of barbiturates should be reduced if sedation is observed. Optimum dosage is mainly determined by seizure control and routine measurement of plasma levels is unnecessary. **Contra-indications, Warnings** *Contra-indication:* Active liver disease. *Side effects:* Liver dysfunction including hepatic failure resulting in fatalities has occurred in patients whose treatment included valproic acid or sodium valproate. Patients most at risk are children under the age of three and those with congenital metabolic disorders, organic brain disease or severe seizure disorders associated with mental retardation. The incidents mainly occurred during the first 6 months of therapy and usually involved multiple anticonvulsant therapy. Clinical symptoms are more helpful than laboratory investigations in the early stages of hepatic failure. The onset of an acute illness, especially within the first 6 months, which may include symptoms of vomiting, lethargy or weakness, drowsiness, anorexia, jaundice or loss of seizure control is an indication for immediate withdrawal of the drug. Evidence to date does not establish which investigation could predict this possible adverse effect; measurement of liver function should be performed in the first 6 months of therapy in those who seem most at risk and those with a prior history of liver disease. Hyperammonaemia without hepatic damage can occur, it is usually transient, but may occasionally present clinically. If so Epilim should be discontinued. Valproic acid inhibits platelet aggregation. Thrombocytopenia has been reported. Spontaneous bruising or bleeding is an indication for withdrawal of medication. Pancreatitis, tremor, weight gain, transient hair loss, increased alertness, aggressiveness, hyperactivity, amenorrhoea, stupor and oedema have been reported. **Drug Interactions** Epilim may potentiate monoamine oxidase inhibitors and other antidepressants. Loss of efficacy of oral contraceptive agents does not appear to be a problem. **Women of Childbearing Age** Valproic acid and sodium valproate, like certain other anticonvulsants, have been shown to be teratogenic in animals. In women of childbearing age the benefits of these compounds should be weighed against the possible hazard suggested by these findings and their pregnancies should be carefully monitored. **Product Licence Numbers** Epilim 200 Enteric Coated 0623/0006. Epilim 500 Enteric Coated 0623/0005. Epilim 100mg crushable tablets 0623/0015. Epilim Syrup 0623/0004. Epilim Liquid 0623/0016. **NHS Cost** Epilim 200 Enteric Coated 100 tablets £6.59. Epilim 500 Enteric Coated 100 tablets, £16.45. Epilim 100mg crushable tablets 100 tablets, £3.99. Epilim Syrup 200ml, £4.03. Epilim Liquid 200ml, £4.03. Further information is available from: Labaz: Sanofi UK Ltd., Floats Rd., Wythenshawe, Manchester M23 9NF. Tel: 061-945 4161.

Sanofi Labaz

Epilim
Sodium Valproate

helps to maintain the normality of life

Indications Epilepsy (generalised tonic-clonic and partial seizures).
Dosage in epilepsy Use a gradually increasing dosage scheme, adjusting to patient's needs. Adults: 100-200mg once or twice daily, increasing slowly up to 800-1,200mg daily; in some cases 1,600mg daily may be necessary. Children: up to 1 year old, 100-200mg daily; aged 1-5 years, 200-400mg daily; aged 5-10 years, 400-600mg daily; aged 10-15 years, 600-1,000mg daily. It may be helpful to monitor plasma drug levels: optimum therapeutic range is 3-10μg/ml (13-42μmols/l).
Side-effects Dizziness and diplopia (usually dose-dependent), less frequently dry mouth, nausea and vomiting. Generalised erythematous rash, disappearing on cessation of therapy. Isolated reports of oedema, hyponatraemia, exfoliative dermatitis, leucopenia, thrombocytopenia, agranulocytosis, aplastic anaemia, cholestatic jaundice and acute renal failure. Blood count should be checked in early stages of treatment.
Precautions Caution in patients taking oral anticoagulants or requiring oral contraception.
In pregnancy, potential benefits of Tegretol must be weighed against potential hazards. Do not administer with, or within two weeks of cessation of, MAOI therapy.
In rats treated with carbamazepine for two years, incidence of liver tumours increased (no evidence of significant bearing on the therapeutic use of the drug). Serum folic acid levels should be observed during anticonvulsant therapy.
Contra-indications Previous drug sensitivity to Tegretol. Do not administer to patients with atrioventricular conduction abnormalities unless paced.
Packs Tablets of 100mg (PL0001/5027) basic NHS price £2.90 per 100, £13.95 per 500; tablets of 200mg (PL0001/5028 £5.38 per 100, £25.93 per 500; tablets of 400mg (PL0001/0088) £10.58 per 100; syrup 100mg/5ml (PL0001/0050) £5.17 per 300ml bottle.
® denotes registered trademark. Full prescribing information is available on request from Geigy Pharmaceuticals, Horsham, West Sussex.

Geigy

Tegretol®
carbamazepine BP

for the effective control of epilepsy

TG1

International coverage of the most important developments in pediatric medicine

PEDIATRIC RESEARCH

An International Journal of Clinical, Laboratory, and Developmental Investigation

Editor-in-Chief: **Delbert A. Fisher, MD**

Every month, **Pediatric Research** puts you in touch with leading authorities in pediatric pulmonology, endocrinology and metabolism, gastroenterology, and nutrition. You'll read about significant new clinical and laboratory results, as selected and reported by an international array of distinguished contributors and editors.

Abstracts of major society meetings worldwide and occasional supplements on specific issues in pediatric health are also part of the package, but the hallmark of **Pediatric Research** is *research*, and lots of it. Each issue contains some 15 original articles — 4 to 6 pages each — on late-breaking investigations into the most difficult problems of childhood disease.

Cystic fibrosis, hypopituitarism, sudden infant death syndrome, protein intolerance, metabolic disorders, and sickle cell anemia are just a few of the subjects covered in recent issues. As advances are made in the understanding and management of these and other baffling childhood disorders, **Pediatric Research** will continue to be there with timely, accurate, and useful reports from leaders in the field. **Monthly**

Personal: $95/yr **Institutions:** $120/yr
In-training: $75/yr *(add $15.00 outside the US)*

FOR FASTEST SERVICE, call 1-800-638-6423
FREE from anywhere in the US except AK. MD residents, call 528-4105 collect.

P.O. Box 23291 Baltimore, Maryland 21203
266 Fulham Road London SW10 9EL England

PEDIATRIC RESEARCH *An International Journal of Clinical, Laboratory, and Developmental Investigation*

Research you can't afford to miss... and an offer you can't afford to pass up

Avoid planned rate increases and ensure uninterrupted service by subscribing to **PEDIATRIC RESEARCH** for up to *3 years* at current rates.

☐ New subscription ☐ Renewal
☐ 3 yrs ☐ 2 yrs ☐ 1 yr
☐ **Personal:** $95/yr ☐ **Institutions:** $120/yr
☐ **In-training:** $75/yr
(add $15.00 outside the US)
☐ check enclosed ☐ bill me
☐ VISA ☐ MasterCard ☐ American Express

card # exp.

signature P.O. #

Williams & Wilkins

MD residents, please add 5% sales tax. Subscriptions outside the US must be prepaid, in US dollars only. *Residents, fellows, interns and students:* when applying for the in-training rate, which is limited to three years, please include institution name and training status. Rates valid through October 31, 1987.

Please allow 8 weeks for delivery of your first issue. Surface mail delivery to countries outside the US may take up to 16 weeks. Airmail rates available upon request.

Name

Address

City State Zip

P.O. Box 23291 Baltimore, Maryland 21203
266 Fulham Road London SW10 9EL England

printed in USA

PDRAD 94454 87

Published by British Medical Association, Tavistock Square, London WC1H 9JR, and printed in England by The Devonshire Press Ltd., Torquay

CONSIDERING WHAT THEY HAD TO GET RIGHT...



IT'S NO WONDER MORE AND MORE DIABETICS USE

HUMAN MIXTARD® 30/70

Neutral Suspension comprising 30% Neutral Insulin Injection and 70% Isophane Insulin Injection (NPH) human insulin (rDNA)

Simple · Convenient · Effective

CONTROL THAT WON'T TIE THEM IN KNOTS

Nordisk Wellcome